Text Size

Piracetam for Treatment of Cocaine Addiction - 3

This study has been completed.
Sponsor:
Collaborator:
University of Pennsylvania
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000198
First received: September 20, 1999
Last updated: June 23, 2005
Last verified: October 1996
History of Changes
  Purpose

The purpose of this study is to evaluate the effects of IV cocaine administration in cocaine dependent subjects maintained on piracetam while they are residing in an inpatient addictions treatment research unit and to subsequently follow these patients in an eight week open label assessment of piracetam in an outpatient treatment program.


Condition Intervention Phase
Cocaine-Related Disorders
 Drug: Piracetam
 Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Piracetam for Treatment of Cocaine Addiction

Resource links provided by NLM:

MedlinePlus related topics: Anxiety
U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Pulse, blood pressure
  • Adverse effects
  • High, anxiety, withdrawal

Estimated Enrollment: 0
Study Start Date: October 1996
  Eligibility

Ages Eligible for Study:   21 Years to 45 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000198

Locations
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
University of Pennsylvania
Investigators
Principal Investigator: Kyle Kampman, M.D. University of Pennsylvania
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00000198     History of Changes
Other Study ID Numbers: NIDA-00238-3, K02-00238-3
Study First Received: September 20, 1999
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Piracetam
Neuroprotective Agents
Protective Agents
 Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Nootropic Agents

ClinicalTrials.gov processed this record on May 23, 2013